{"": [105, 113, 0], "Background": [114, 272, 0], "Methods": [273, 563, 0, 6959, 19578, 1], "Findings": [564, 1185, 0], "Interpretation": [1186, 1396, 0], "Funding": [1397, 1976, 0], "Research in context": [1977, 3617, 0], "Introduction": [3618, 6958, 0], "Mice": [6968, 7430, 0], "Cell lines": [7431, 7903, 0], "Viruses": [7904, 8143, 0], "Construction and Generation of PD1-based DNA and live attenuated influenza virus (LAIV)-based vaccine": [8144, 9972, 0], "Animal immunization and SARS-CoV-2 challenges": [9973, 11551, 0], "Enzyme-linked immunosorbent assay (ELISA)": [11552, 12708, 0], "Pseudotyped viral neutralization assay": [12709, 14029, 0], "Surface and intracellular cytokine staining (ICS)": [14030, 16011, 0], "Viral RNA quantification": [16012, 16639, 0], "Plaque assay": [16640, 17082, 0], "Histopathology and Immunofluorescence (IF) Staining": [17083, 18371, 0], "Statistical analysis": [18372, 19240, 0], "Animal study approval": [19241, 19424, 0], "Role of funding source": [19425, 19578, 0], "Construction and characterization of PD1-based DNA and influenza-based vaccines": [19588, 21597, 0], "Systemic and mucosal antibody responses of vaccine regimens": [21598, 24523, 0], "Acute and memory T cell responses of vaccine regimens": [24524, 27602, 0], "Protective efficacy against intranasal SARS-CoV-2 infection": [27603, 30395, 0], "Infection-recalled NAb for correlate of protection": [30396, 31911, 0], "SARS-CoV-2 prevention in both upper and lower respiratory tracts of K18-hACE2 mice": [31912, 35488, 0], "Both NAb and antigen-specific CD8 T cells associated with virus control in K18-hACE2 mice": [35489, 36721, 0], "LAIV-CA4-RBD boosted the immunogenicity of vaccines in emergency use": [36722, 39076, 0], "Vaccine-induced NAbs cross-neutralize global SARS-CoV-2 variants of concern": [39077, 41438, 0], "Results": [19579, 41438, 1], "Discussion": [41439, 48397, 0], "Declaration of interests": [48398, 48740, 0]}